Compare Equinor ASA (EQNR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Repligen Corporation Common Stock — how do they compare? Equinor ASA trades at $44.94 (market cap $105.42B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Equinor ASA is far larger — about 9.5× Repligen Corporation Common Stock's market cap, and Equinor ASA pays a 3.47% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Repligen Corporation Common Stock for 0 Days on average.
| EQNR | RGEN | |
|---|---|---|
Market Cap | $105.42B | $11.14B |
Volume | 4,977,357 | 1,259,263 |
Sector | Energy | Health |
52-Week High | $45.75 | $194.57 |
52-Week Low | $22.41 | $102.87 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $114.11B | $11.02B |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $45.29, up 3.07% today, with a bullish technical signal from moving averages and a consensus analyst price target of $87.50 implying significant upside. Recent earnings show a mix of beats and one miss, while fundamentals reveal strong cash flow from operations of $20.0B in 2025 and attractive valuation ratios, including a P/E of 12.2 and EV/EBITDA of 2.47. The company is expanding its LNG portfolio and executing share buybacks, supporting positive sentiment.
The outlook for EQNR is positive, driven by undervaluation relative to analyst targets and strategic growth in LNG and carbon capture. Key risks include volatility in energy prices and execution of expansion plans. Earnings growth and dividend stability remain central to investor appeal, with the stock positioned for potential appreciation if operational targets are met.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
